Skip to Content

Stivarga Approval History

Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.

Development History and FDA Approval Process for Stivarga

Apr 27, 2017Approval FDA Expands Approved Use of Stivarga (regorafenib) to Treat Hepatocellular Carcinoma
Feb 25, 2013Approval FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
Sep 27, 2012Approval FDA Approves Stivarga for Advanced Colorectal Cancer
Aug 30, 2012Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Jun 28, 2012U.S. FDA Grants Priority Review to the New Drug Application for Bayer's Regorafenib to Treat Patients with Metastatic Colorectal Cancer
May 23, 2012Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.